Recombinant Human ICAM-1/CD54 Fc Chimera Avi-tag Protein, CF

When Human ICAM-1/CD54 (Clone 14C11) Antibody (Catalog # MAB720) is immobilized at 0.5 μg/mL (100 μL/well), Biotinylated Recombinant Human ICAM-1/CD54 Fc Chimera Avi-tag (Catalog # AVI720) binds with an ED50 of 3-18 ng/mL.

2 μg/lane of Biotinylated Recombinant Human ICAM-1/CD54 Fc Chimera Avi-tag (Catalog # AVI720) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 95-125 kDa and 195-215 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human ICAM-1/CD54 Fc Chimera Avi-tag Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Human ICAM-1 (14C11) Antibody (Catalog # MAB720) is immobilized at 0.5 µg/mL (100 µL/well), Biotinylated Recombinant Human ICAM-1/CD54 Fc Chimera Avi-tag (Catalog # AVI720) binds with an ED₅₀ of 3-18 ng/mL. Measured by its ability to support the adhesion of HSB2 human peripheral blood acute lymphoblastic leukemia cells. The ED₅₀ for this effect is 0.3-2.7 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human ICAM-1/CD54 protein
  

  Human ICAM-1 (Gln28-Glu480) Accession # P05362	IEGRMD	Human IgG1 (Pro100-Lys330)	GG	Avi-tag

• Accession #: P05362
• N-terminal Sequence:

  Gln28 inferred from enzymatic pyroglutamate treatment revealing Thr29

• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
  • Bioactivity2
• Theoretical MW: 78 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 95-125 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human ICAM-1/CD54 Fc Chimera Avi-tag Protein, CF

• BB2
• CD54 antigen
• CD54
• cell surface glycoprotein P3.58
• human rhinovirus receptor
• ICAM1
• ICAM-1
• intercellular adhesion molecule 1 (CD54), human rhinovirus receptor
• intercellular adhesion molecule 1
• Major group rhinovirus receptor
• P3.58

Background

ICAM-1 (Intercellular Adhesion Molecule-1), also known as CD54, is a transmembrane cell adhesion glycoprotein and a member of the immunoglobulin supergene family. The ICAM sub-family consists of five members, ICAM-1 through ICAM-5, and they vary in their tissue expression and number of Ig-like domains in the extracellular domain (ECD). Full-length ICAM-1 contains five Ig-like domains in the ECD, a single transmembrane domain and short intracellular domain. Alternative splicing of ICAM-1 results in at least six membrane-bound forms and one soluble form (1). The ECD of mature, full-length human ICAM-1 shares 78% and 54% amino acid sequence identity with rat and mouse ICAM-1, respectively. ICAM-1 plays an important role in both innate and adaptive immune responses and is upregulated in endothelial and epithelial cells at sites of inflammation (2, 3). ICAM-1 mediates vascular adhesion and paracellular migration of leukocytes expressing activated LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) 2, 3). It also binds several non-integrin ligands including CD43/Sialophorin, Fibrinogen, Hyaluronan, rhinoviruses, and Plasmodium falciparum-infected erythrocytes (4-8). Soluble ICAM-1 promotes angiogenesis and serves as an indicator of vascular endothelial cell activation or damage (9). Elevated levels of soluble ICAM-1 are associated with cardiovascular disease, type 2 diabetes, organ transplant dysfunction, oxidant stress, increased abdominal fat mass, hypertension, liver disease, certain malignancies, and cerebral malaria (10-18). More recently, ICAM-1 was shown to be a novel regulator of group 2 innate lymphoid cells (ILC2s) which play a key role in allergic airway inflammation (19).

1. Robledo O. et al. (2003) Eur J Immunol. 33:1351.
2. Springer T.A. (1994) Cell. 76:301.
3. Yang, L. et al. (2005) Blood. 106:584.
4. Rosenstein, Y. et al. (1991) Nature 354:233.
5. Pluskota, E. and S.E. D’Souza (2000) Eur. J. Biochem. 267:4693.
6. McCourt, P.A.G. et al. (1994) J. Biol. Chem. 269:30081.
7. Kirchberger, S. et al. (2006) Immunobiology 211:537.
8. Chakravorty S.J. and A. Craig (2005) Eur J. Cell Biol. 84:15.
9. Ding, Y. et al. (2019) Ann. Clin. Transl. Neurol. 6:945.
10. Benson, V. et al. (2007) Curr. Mol. Med. 7:219.
11. Hoogeveen, R.C. et al. (2007) Diabetologia 50:36.
12. Covarrubias, M. et al. (2007) Am. J. Transplant. 7:2573.
13. Cottone, S. et al. (2007) J. Hypertens. 25:423.
14. Brake, D.K. et al. (2006) Am. J. Physiol. Cell Physiol. 291:C1232.
15. Madej, A. et al. (2005) Pharmacol. Rep. 57:878.
16. El-Gohary, A.M. et al. (2004) Egypt. J. Immunol. 11:109.
17. Christiansen, I. et al. (1996) Br. J. Haematol. 92:639.
18. Kang, X. et al. (2005) World J. Gastroenterol. 11:4250.
19. Lei, A. et al. (2018) JEM. 215:2157.

Bioinformatics

• Uniprot:
  • P05362()